[{"orgOrder":0,"company":"CSL","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ARCT-154","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CSL \/ CSL","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ CSL"},{"orgOrder":0,"company":"CSL","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Self-Amplifying Mrna Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CSL \/ Arcturus Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Arcturus Therapeutics"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"H1N1 antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"H1N1 antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"H1N1 antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"H1N1 antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"H1N1 antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"H1N1 antigen","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Aqiv","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Termination","leadProduct":"ARCT-154","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CSL","amount2":4.5,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":4.5,"dosageForm":"Intramuscular Injection","sponsorNew":"CSL \/ CSL","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ CSL"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Adjuvanted Quadrivalent Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ARCT-154","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"CSL \/ CSL","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ CSL"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Adjuvanted SARS-CoV-2 Subunit Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"aH5N6c","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"aH5N8c","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular","sponsorNew":"Seqirus \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"8","companyTruncated":"Seqirus \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"Seqirus","sponsor":"Biomedical Advanced Research and Development Authority","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"MF59 Adjuvanted H2N3 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Seqirus \/ Biomedical Advanced Research and Development Authority","highestDevelopmentStatusID":"6","companyTruncated":"Seqirus \/ Biomedical Advanced Research and Development Authority"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Uniqure","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":2.0499999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":2.0499999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ CSL Behring","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ CSL Behring"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Orsini Specialty Pharmacy","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Orsini Specialty Pharmacy","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Orsini Specialty Pharmacy"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Human Alpha1-Proteinase Inhibitor","moa":"Leukocyte elastase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"GERMANY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Partnership","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Approved FDF","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Vifor \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CSL Vifor \/ Vifor Pharma"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"AUSTRALIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"CSL Vifor","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Acquisition","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Approved FDF","graph3":"CSL","amount2":11.699999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":11.699999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ CSL","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ CSL"},{"orgOrder":0,"company":"CSL","sponsor":"CSL Vifor","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"SWITZERLAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Acquisition","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Approved FDF","graph3":"CSL","amount2":11.699999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":11.699999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ CSL","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ CSL"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"AUSTRALIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"AUSTRALIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CARA Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL Vifor \/ CARA Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"CSL Vifor \/ CARA Therapeutics"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"AUSTRALIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Hematology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"CARA Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL \/ CARA Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ CARA Therapeutics"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Albutrepenonacog Alpha","moa":"Factor X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL Vifor \/ Tigermed","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ Tigermed"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Uniqure","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ CSL Behring","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ CSL Behring"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Uniqure","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":2.0499999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ CSL Behring","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ CSL Behring"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Uniqure","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":2.0499999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":2.0499999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ CSL Behring","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ CSL Behring"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Hyperimmune Immunoglobulin","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ National Institutes of Health","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ National Institutes of Health"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Angion Biomedica","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Vifor \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ Vifor Pharma"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Angion Biomedica","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Vifor \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ Vifor Pharma"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Angion Biomedica","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL Vifor \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ Vifor Pharma"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Angion Biomedica","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"CSL Vifor","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0.029999999999999999,"dosageForm":"Intravenous Injection","sponsorNew":"CSL Vifor \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ Vifor Pharma"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Fusion Protein Linking Coagulation Factor Ix","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Lyophilized Powder for Solution","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Apolipoprotein A-I, Human","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Apolipoprotein A-I, Human","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Apolipoprotein A-I, Human","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"BE1116","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CSL222","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CSL511","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Lonoctocog Alfa","moa":"Coagulation factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Lyophilized Powder for Solution","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"BioXcel Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Vifor \/ CSL Vifor","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ CSL Vifor"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"CSL889","moa":"Hemojuvelin","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL Vifor \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Garadacimab","moa":"F12a","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Garadacimab","moa":"F12a","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Angion Biomedica","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Vifor \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ Vifor Pharma"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Human Rho D Immune Globulin","moa":"IgG","graph1":"Immunology","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CSL324","moa":"Granulocyte colony stimulating factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CSL312","moa":"Coagulation factor XII (F12)","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Translational Sciences","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"AUSTRALIA","productType":"Antibody","year":"2022","type":"Licensing Agreement","leadProduct":"TS23","moa":"Alpha-2 plasmin","graph1":"Hematology","graph2":"Phase I","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL \/ Translational Sciences","highestDevelopmentStatusID":"6","companyTruncated":"CSL \/ Translational Sciences"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Nephrology","graph2":"Phase I","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL Vifor \/ Tigermed","highestDevelopmentStatusID":"6","companyTruncated":"CSL Vifor \/ Tigermed"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"CSL889","moa":"Hemojuvelin","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CSL760","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CSL324","moa":"Granulocyte colony stimulating factor receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"SAB Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Partnership","leadProduct":"SAB-185","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ CSL Behring","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ CSL Behring"},{"orgOrder":0,"company":"Seqirus","sponsor":"Amarin","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Seqirus","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Oral Capsule","sponsorNew":"Seqirus \/ Seqirus","highestDevelopmentStatusID":"15","companyTruncated":"Seqirus \/ Seqirus"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CARA Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CSL Vifor \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CSL Vifor \/ Vifor Pharma"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Akebia Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vadadustat","moa":"Egl nine homolog 1 | Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 3","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"CSL Vifor \/ CSL Vifor","highestDevelopmentStatusID":"15","companyTruncated":"CSL Vifor \/ CSL Vifor"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Akebia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Vadadustat","moa":"Egl nine homolog 1 | Hypoxia-inducible factor prolyl hydroxylase 1 | Egl nine homolog 3","graph1":"Hematology","graph2":"Approved FDF","graph3":"CSL Vifor","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0.050000000000000003,"dosageForm":"Oral Tablet","sponsorNew":"CSL Vifor \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CSL Vifor \/ Vifor Pharma"},{"orgOrder":0,"company":"CSL","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CSL \/ ChemoCentryx","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ ChemoCentryx"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Patiromer Sorbitex Calcium","moa":"Potassium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL \/ Fresenius Kabi AG","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Fresenius Kabi AG"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Patiromer Sorbitex Calcium","moa":"Potassium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Patiromer Sorbitex Calcium","moa":"Potassium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Patiromer Sorbitex Calcium","moa":"Potassium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Patiromer Sorbitex Calcium","moa":"Potassium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Iron Sucrose","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Chewable","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Iron Sucrose","moa":"Undisclosed","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Chewable","sponsorNew":"CSL \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"OPKO Health","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Termination","leadProduct":"Calcifediol","moa":"Vitamin D receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CSL Vifor \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CSL Vifor \/ Vifor Pharma"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Travere Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CSL Vifor \/ CSL Vifor","highestDevelopmentStatusID":"15","companyTruncated":"CSL Vifor \/ CSL Vifor"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Travere Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CSL Vifor \/ CSL Vifor","highestDevelopmentStatusID":"15","companyTruncated":"CSL Vifor \/ CSL Vifor"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CARA Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CSL Vifor \/ CARA Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"CSL Vifor \/ CARA Therapeutics"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Travere Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"CSL Vifor \/ CSL Vifor","highestDevelopmentStatusID":"15","companyTruncated":"CSL Vifor \/ CSL Vifor"},{"orgOrder":0,"company":"CSL","sponsor":"Esperion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Bempedoic Acid","moa":"||ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"CSL","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"CSL \/ CSL","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ CSL"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CARA Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CSL Vifor \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CSL Vifor \/ Vifor Pharma"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CARA Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CSL Vifor \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CSL Vifor \/ Vifor Pharma"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CARA Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CSL Vifor \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CSL Vifor \/ Vifor Pharma"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CARA Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CSL Vifor \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CSL Vifor \/ Vifor Pharma"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CARA Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Difelikefalin Acetate","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"CSL Vifor","amount2":0.44,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0.44,"dosageForm":"Oral Tablet","sponsorNew":"CSL Vifor \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CSL Vifor \/ Vifor Pharma"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Phase III","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"CSL Vifor \/ Tigermed","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ Tigermed"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Phase III","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"CSL Vifor \/ CSL Vifor","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ CSL Vifor"},{"orgOrder":0,"company":"CSL","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CSL \/ Amgen Inc","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Amgen Inc"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Travere Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"CSL Vifor \/ CSL Vifor","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ CSL Vifor"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Travere Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"CSL Vifor","amount2":0.19,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0.19,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"CSL Vifor \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ Vifor Pharma"},{"orgOrder":0,"company":"CSL","sponsor":"Travere Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"CSL \/ Travere Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"CSL \/ Travere Therapeutics"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Labcorp","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vamifeport","moa":"Ferroportin","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CSL Vifor \/ LabCorp","highestDevelopmentStatusID":"8","companyTruncated":"CSL Vifor \/ LabCorp"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Labcorp","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vamifeport","moa":"Ferroportin","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CSL Vifor \/ LabCorp","highestDevelopmentStatusID":"8","companyTruncated":"CSL Vifor \/ LabCorp"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Fortrea","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vamifeport","moa":"Ferroportin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CSL Vifor \/ Fortrea","highestDevelopmentStatusID":"8","companyTruncated":"CSL Vifor \/ Fortrea"},{"orgOrder":0,"company":"CSL","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avacopan","moa":"C5a anaphylatoxin chemotactic receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CSL \/ Amgen Inc","highestDevelopmentStatusID":"8","companyTruncated":"CSL \/ Amgen Inc"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vamifeport","moa":"SLC40A1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vamifeport","moa":"SLC40A1","graph1":"Undisclosed","graph2":"Phase I","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CSL Vifor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CSL Vifor \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vamifeport","moa":"SLC40A1","graph1":"Undisclosed","graph2":"Phase I","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"CSL787","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"SAB Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Immunology","graph2":"Undisclosed","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"CSL Behring \/ SAB Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"CSL Behring \/ SAB Biotherapeutics"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Garadacimab","moa":"F12a","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Garadacimab","moa":"F12a","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Garadacimab","moa":"F12a","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Lyophilized Human C1-esterase","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Human C1 Esterase Inhibitor","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Garadacimab","moa":"F12a","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CSL312","moa":"Coagulation factor XII (F12)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"CSL312","moa":"Coagulation factor XII (F12)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CSL312","moa":"Coagulation factor XII (F12)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Garadacimab","moa":"F12a","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Garadacimab","moa":"F12a","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Garadacimab","moa":"F12a","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Garadacimab","moa":"F12a","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Immune Globulin","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Liquid","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Garadacimab","moa":"F12a","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"CSL Behring","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Clazakizumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL Behring \/ CSL Behring","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ CSL Behring"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CSL312","moa":"Coagulation factor XII (F12)","graph1":"Undisclosed","graph2":"Phase I","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"CSL312","moa":"Coagulation factor XII (F12)","graph1":"Undisclosed","graph2":"Phase I","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Athenex","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Seqirus \/ Seqirus","highestDevelopmentStatusID":"15","companyTruncated":"Seqirus \/ Seqirus"},{"orgOrder":0,"company":"Seqirus","sponsor":"Athenex","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Seqirus \/ Seqirus","highestDevelopmentStatusID":"15","companyTruncated":"Seqirus \/ Seqirus"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avacopan","moa":"||C5a anaphylatoxin chemotactic receptor","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Vifor \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Vifor \/ Inapplicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Zeria Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Patiromer Sorbitex Calcium","moa":"Potassium","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Vifor \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CSL Vifor \/ Vifor Pharma"},{"orgOrder":0,"company":"CSL","sponsor":"Pharmanovia","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Safinamide Methanesulfonate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL \/ Pharmanovia","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Pharmanovia"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Travere Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sparsentan","moa":"Endothelin receptor ET-A | Type-1 angiotensin II receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Vifor \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"CSL Vifor \/ Vifor Pharma"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Immune Globulin G","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"Influenza A (H5N1) Monovalent Vaccine, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seqirus \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Seqirus \/ BARDA"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Influenza A (H5N1) Monovalent Vaccine, Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Arcturus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Self-Amplifying Mrna Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL \/ CSL","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ CSL"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Seoul National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Fe","graph1":"Neurology","graph2":"Phase IV","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSL Vifor \/ CSL Vifor","highestDevelopmentStatusID":"11","companyTruncated":"CSL Vifor \/ CSL Vifor"},{"orgOrder":0,"company":"CSL","sponsor":"Vitaeris","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CANADA","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Clazakizumab","moa":"Interleukin-6","graph1":"Immunology","graph2":"Phase III","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL \/ CSL","highestDevelopmentStatusID":"10","companyTruncated":"CSL \/ CSL"},{"orgOrder":0,"company":"Seqirus","sponsor":"ARS Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Licensing Agreement","leadProduct":"Epinephrine","moa":"Adrenergic receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Seqirus \/ Seqirus","highestDevelopmentStatusID":"10","companyTruncated":"Seqirus \/ Seqirus"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ferric Carboxymaltose","moa":"Iron","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Vifor \/ CSL Vifor","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ CSL Vifor"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Cell-Derived Quadrivalent Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Trivalent Influenza Vaccine, MF59-Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Trivalent Influenza Vaccine, MF59-Adjuvanted","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CSL300","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CSL346","moa":"VEGF-B","graph1":"Nephrology","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Phase III","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Vifor \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Vifor \/ Inapplicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"aH5N1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"aQII-1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"MF59-Adjuvanted Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Quadrivalent Influenza Vaccine","moa":"H1N1 antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"H5N8 A\/Astrakhan Virus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Pre-Filled Injection","sponsorNew":"CSL \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"CSL \/ BARDA"},{"orgOrder":0,"company":"CSL Behring","sponsor":"HCmed Innovations","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Human Plasma-Derived Polyvalent Immunoglobulin G","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Aerosol","sponsorNew":"CSL Behring \/ HCmed Innovations","highestDevelopmentStatusID":"6","companyTruncated":"CSL Behring \/ HCmed Innovations"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CSL730","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CSL324","moa":"Granulocyte colony stimulating factor receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CSL040","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Commonwealth Of Australia","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"V451","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ Commonwealth Of Australia","highestDevelopmentStatusID":"6","companyTruncated":"CSL Behring \/ Commonwealth Of Australia"},{"orgOrder":0,"company":"CSL","sponsor":"CSL","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"V451","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL \/ CSL","highestDevelopmentStatusID":"6","companyTruncated":"CSL \/ CSL"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Sa-Mrna Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"CSL","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal","sponsorNew":"CSL \/ CSL","highestDevelopmentStatusID":"6","companyTruncated":"CSL \/ CSL"},{"orgOrder":0,"company":"CSL","sponsor":"University Of Queensland","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Squalene","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL \/ University Of Queensland","highestDevelopmentStatusID":"4","companyTruncated":"CSL \/ University Of Queensland"},{"orgOrder":0,"company":"Seqirus","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Agreement","leadProduct":"H5N8 A\/Astrakhan Virus Vaccine","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Seqirus","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Intramuscular Pre-Filled Injection","sponsorNew":"Seqirus \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"Seqirus \/ BARDA"},{"orgOrder":0,"company":"Seqirus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"saRNA Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seqirus \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Seqirus \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"CSL","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL \/ CSL","highestDevelopmentStatusID":"2","companyTruncated":"CSL \/ CSL"},{"orgOrder":0,"company":"CSL Behring","sponsor":"The University of Pittsburgh School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ CSL Behring","highestDevelopmentStatusID":"1","companyTruncated":"CSL Behring \/ CSL Behring"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Undisclosed","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"CSL Behring \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by CSL

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Andembry (garadacimab) uniquely inhibits the plasma protein, FXIIa. It is approved for hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

                          Product Name : Andembry

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          June 16, 2025

                          Lead Product(s) : Garadacimab

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Filspari (sparsentan) is an oral drug designed to selectively target two critical pathways - endothelin-1 and angiotensin II. It is approved for the treatment of IgA Nephropathy.

                          Product Name : Filspari

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 29, 2025

                          Lead Product(s) : Sparsentan

                          Therapeutic Area : Nephrology

                          Highest Development Status : Approved FDF

                          Recipient : Travere Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : CSL Seqirus gains exclusive rights to commercialize Nexletol (bempedoic acid) and Nexlizet (bempedoic acid and ezetimibe) in Australia and New Zealand for cardiovascular disease.

                          Product Name : Nexlizet

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 03, 2025

                          Lead Product(s) : Bempedoic Acid,Ezetimibe

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Recipient : Esperion Therapeutics

                          Deal Size : $5.0 million

                          Deal Type : Licensing Agreement

                          blank

                          04

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Andembry (garadacimab) is a novel Factor XIIa-inhibitory monoclonal antibody. It is under development as a once-monthly subcutaneous prophylactic treatment for attacks related to HAE.

                          Product Name : Andembry

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          February 20, 2025

                          Lead Product(s) : Garadacimab

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Kostaive is an self-amplifying mRNA (sa-mRNA) vaccine based on the SARS-CoV-2 D614G variant spike protein. This covid-19 vaccine for initial vaccination and booster for adults 18 years and older.

                          Product Name : Kostaive

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          February 14, 2025

                          Lead Product(s) : Self-Amplifying Mrna Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Arcturus Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Andembry (garadacimab) is a novel Factor XIIa-inhibitory monoclonal antibody. It is under development as a once-monthly subcutaneous prophylactic treatment for attacks related to HAE.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          February 13, 2025

                          Lead Product(s) : Garadacimab

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          December 17, 2024

                          Lead Product(s) : Lonoctocog Alfa

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : CSL312 (garadacimab) is a novel Factor XIIa-inhibitory monoclonal antibody. It is under development as a once-monthly subcutaneous prophylactic treatment for attacks related to HAE.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          December 13, 2024

                          Lead Product(s) : Garadacimab

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : BXCL501 (dexmedetomidine Hc;) is being evaluated in the late-stage clinical trials studies for the treatment of Agitation Associated with Bipolar Disorders and Schizophrenia.

                          Product Name : Igalmi

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 11, 2024

                          Lead Product(s) : Dexmedetomidine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Recipient : BioXcel Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          November 21, 2024

                          Lead Product(s) : CSL889

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank